78 stories
BPC-157 is a synthetic 15-amino-acid fragment derived from a gastric protein. It became one of the most-requested research peptides in the wellness and longevity market on the strength of preclinical data showing accelerated tendon, ligament, and gut tissue repair. Most of that work sits in rodent or in-vitro studies rather than in human trials.
The regulatory picture shifted decisively on July 23, 2026. The FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with 1 abstention to recommend adding BPC-157 to the Section 503A bulks list, overriding the June 29-30 FDA career-staff briefing documents that recommended against it. The vote is advisory; formal rulemaking would take approximately 6-18 months before compounding pharmacies could legally prepare BPC-157 under the 503A framework. Prior to the PCAC vote, BPC-157 sat in Category 2 (insufficient information to evaluate) and was the subject of DOJ action, state medical-board enforcement against clinics, and UK MHRA notices.
The clinical evidence base remains thin. A 2026 STAT and Undark investigation sharpened the point: nearly all of the roughly 200 BPC-157 studies on PubMed list Croatian researcher Predrag Sikiric or a close colleague as an author, the work carries undisclosed patent and commercial conflicts, and only three human studies have been published. Stories here cover new preclinical work, regulatory action, and any movement toward registered human trials. See #pcac and #peptide-compounding for adjacent threads.
London Standard investigation exposes consumers self-injecting BPC-157 and CJC-1295 sourced from Discord groups and online sellers, bypassing medical oversight. UK solicitors warn clinics are on 'very shaky ground.'
Updated explainer clarifying BPC-157 is not outright banned but in Category 2 requiring further investigation. Discusses potential shifts after public statements about moving peptides back to Category 1.
Physician William Meller describes treating a patient in anaphylaxis after self-injecting online peptides, and critiques RFK Jr.'s plan to move ~14 compounds off the FDA restricted list.
Investigation into men injecting BPC-157 and Thymosin Alpha-1 from unregulated internet suppliers. Doctors warn of severe allergic reactions and potential cancer risk from growth-pathway compounds.
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.
In-depth review examined 544 BPC-157 papers and found only 3 human studies and zero randomized controlled trials. Author recommends most people avoid it until stronger evidence emerges.